Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106171 · ClinicalTrials.gov registry record · Phase 4
Anti-HIV Medications for People Recently Infected With HIV
A Phase 4 study of HIV Infections, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 113
- Enrollment target
- 5
- Study locations
NCT00106171 is a Phase 4 study of HIV Infections that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 113 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT00106171, a Phase 4 study of HIV Infections, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 113 participants
- Enrollment target
- 5
- Study locations
Study Summary
It is not known if anti-HIV treatment for recently infected patients improves long-term patient prognosis. The purpose of this study is to determine if a one year course of anti-HIV medications slows progression of HIV disease in adults recently infected with HIV. Study hypothesis: A one-year course of HAART administered during acute or early seroconversion may slow the progression of HIV infection.
Conditions Studied
Interventions
- DRUG Highly active antiretroviral therapy (HAART)
Study Locations (5)
Ontario
- Sunnybrook Health Sciences Ctr. - Toronto
- Canadian Immunodeficiency Research Collaborative (CIRC) Inc. - Toronto
Maryland
- Johns Hopkins University - Baltimore
British Columbia
- University of British Columbia - Vancouver
Quebec
- CHUM - Hotel-Dieu - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2005-05 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106171
The ClinicalTrials.gov registry entry for NCT00106171 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (75% lower). The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Highly active antiretroviral therapy (HAART) is the first listed.
NCT00106171 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ontario, Maryland, British Columbia.
Frequently Asked Questions
What is clinical trial NCT00106171 about?
NCT00106171 is a clinical study titled "Anti-HIV Medications for People Recently Infected With HIV". It is not known if anti-HIV treatment for recently infected patients improves long-term patient prognosis. The purpose of this study is to determine if a one year course of anti-HIV medications slows progression of HIV disease in adults recently infected with HIV. Study hypothesis: A one-year cours...
What is the current status of trial NCT00106171?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 113 participants. The study started on 2005-05. Estimated completion is 2012-05.
What conditions does trial NCT00106171 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00106171?
The interventions under investigation include: Highly active antiretroviral therapy (HAART) (DRUG).
Who is sponsoring clinical trial NCT00106171?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00106171 being conducted?
This trial has 5 study locations across Maryland, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.